Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Operating Leases: 2021-2024

Historic Operating Leases for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $11.8 million.

  • ProQR Therapeutics N.V's Operating Leases fell 4.45% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 4.45%. This contributed to the annual value of $11.8 million for FY2024, which is 20.94% down from last year.
  • Latest data reveals that ProQR Therapeutics N.V reported Operating Leases of $11.8 million as of FY2024, which was down 20.94% from $15.0 million recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Operating Leases high stood at $17.5 million for FY2021, and its period low was $11.8 million during FY2024.
  • In the last 3 years, ProQR Therapeutics N.V's Operating Leases had a median value of $14.1 million in 2022 and averaged $13.6 million.
  • Per our database at Business Quant, ProQR Therapeutics N.V's Operating Leases rose by 6.14% in 2023 and then decreased by 20.94% in 2024.
  • Yearly analysis of 4 years shows ProQR Therapeutics N.V's Operating Leases stood at $17.5 million in 2021, then fell by 19.25% to $14.1 million in 2022, then rose by 6.14% to $15.0 million in 2023, then dropped by 20.94% to $11.8 million in 2024.